United Therapeutics’ (UTHR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of United Therapeutics (NASDAQ:UTHR) in a research report released on Thursday, Benzinga reports. HC Wainwright currently has a $400.00 price objective on the biotechnology company’s stock.

Several other research analysts also recently commented on UTHR. UBS Group raised their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a buy rating in a research note on Monday, July 8th. The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a neutral rating in a research report on Friday, May 3rd. Bank of America cut their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an underperform rating on the stock in a research report on Thursday. Morgan Stanley downgraded shares of United Therapeutics from an overweight rating to an equal weight rating and lifted their price objective for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an overweight rating in a research report on Tuesday, May 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $326.42.

United Therapeutics Price Performance

UTHR stock traded down $3.78 during trading on Thursday, hitting $324.01. 34,518 shares of the company’s stock traded hands, compared to its average volume of 492,381. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $343.98. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The business has a fifty day simple moving average of $307.24 and a 200 day simple moving average of $260.22. The stock has a market capitalization of $14.37 billion, a price-to-earnings ratio of 15.50, a P/E/G ratio of 1.01 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.87%. United Therapeutics’s revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the business posted $5.24 EPS. As a group, research analysts expect that United Therapeutics will post 25.59 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $337.40, for a total transaction of $1,214,640.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $43,862. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $337.40, for a total transaction of $1,214,640.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $43,862. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the sale, the director now directly owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. Insiders sold 98,644 shares of company stock worth $29,697,857 in the last three months. Corporate insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter worth $100,519,000. Swedbank AB purchased a new stake in shares of United Therapeutics during the first quarter worth $97,316,000. Nordea Investment Management AB grew its holdings in shares of United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares in the last quarter. Avidity Partners Management LP purchased a new stake in shares of United Therapeutics during the fourth quarter worth $52,158,000. Finally, Canada Pension Plan Investment Board boosted its position in shares of United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after acquiring an additional 153,700 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.